Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

339 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective multicentre randomised controlled trial comparing the outcomes from Intracorporeal RARC (iRARC) with open radical cystectomy (ORC) in patients with bladder cancer. The study will recruit patients with non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC) who have selected radical cystectomy for the treatment of bladder cancer. The time of interest for measurement of the primary outcomes will be 90 days post-surgery.

Eligible patients will include those receiving neo-adjuvant chemotherapy (typically gemcitabine and cisplatin) and those having either an ileal conduit or a neo-bladder reconstruction.

Patients who have selected radical cystectomy after appropriate counselling and following a specialist multi-disciplinary team (SMDT) recommendation, will be approached and asked to consent for this study.

Consenting participants will be randomised 1:1 to either iRARC or ORC. Patients will be followed for a minimum of 90 days post-surgery.

The study will be conducted in National Health Service (NHS) Trusts designated as Cancer Centres.

Patients will be stratified by

* Type of urinary diversion (Continent diversion or ileal conduit)
* Performance status
* Centre Trial assessments will be conducted at baseline (before surgery), whilst participants are on admission and then 5, 12, 26 weeks,1 year and 18 months post surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer

NCT02699853

Stage 0is Bladder Urothelial Carcinoma Stage I Bladder Urothelial Carcinoma Stage II Bladder Urothelial Carcinoma +1 more

TERMINATED NA

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

NCT01157676

Bladder Cancer Requiring Cystectomy

COMPLETED NA

Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer

NCT01196403

Bladder Cancer

UNKNOWN PHASE2

Protocol of the Italian Radical Cystectomy Registry

NCT04228198

Bladder Cancer

UNKNOWN

Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy

NCT06170177

Muscle-Invasive Bladder Carcinoma Muscle Invasive Bladder Urothelial Carcinoma Bladder Cancer TNM Staging +14 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Radical cystectomy (RC) represents the gold standard treatment for invasive bladder cancer. Reductions in morbidity and mortality from this operation have occurred in recent years through refined anaesthesia, surgical techniques, and centralization of services in high volume centres. The multimodal concept of enhanced recovery after RC (ERAS), which includes pre, intra and post operative steps, has also helped to reduce the length of stay and complications after RC further.

For most abdominal surgery, it is recognized that minimally invasive surgery is less morbid than open surgery, and produces improvements in post-operative recovery without altering the curative nature of the procedure. However, to date, there is little or conflicting evidence of any benefit from minimally invasive surgery over open surgery for RC. This may reflect the complex nature of this procedure (involving surgery to both the urinary and gastro-intestinal tracts), limitations of the current evidence or that there is no benefit. To date, three prospective trials have compared RARC with open RC (ORC). However, each has been limited by sample size and design, or their application of RARC with extra-corporeal reconstruction or have yet to report.

The investigators believe that there are no studies (reported or planned) that have compared optimal RARC (e.g. with intra-corporeal reconstruction) with optimal ORC (e.g. high volume centre using ERAS). In addition, the investigators believe none have adequately assessed the rehabilitation from RC. As such, the investigators now propose a prospective RCT to randomize eligible patients to either ORC or RARC. The investigators will focus upon measures of functional recovery and the return to normal activities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iRARC

Intracorporeal Robot Assisted Radical Cystectomy

Group Type ACTIVE_COMPARATOR

Intracorporeal Robot Assisted Radical Cystectomy

Intervention Type PROCEDURE

Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration

Open Radical Cystectomy (ORC)

Open Radical Cystectomy

Group Type ACTIVE_COMPARATOR

Open Radical Cystectomy

Intervention Type PROCEDURE

Removal of bladder and adjacent organs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intracorporeal Robot Assisted Radical Cystectomy

Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration

Intervention Type PROCEDURE

Open Radical Cystectomy

Removal of bladder and adjacent organs

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be over 18 years of age.
* Male or female
* Histopathological confirmation of bladder cancer (UCC, SCC, adenocarcinoma or rare variant)
* CIS or stage pTa or pT1 or ≥pT2 or mobile bladder mass on bimanual examination under anaesthesia (see Section 22: Definitions for TNM definitions)
* Node status ≤ N1 on imaging criteria or PET -ve outside pelvis
* ECOG grade 0, 1, 2 or 3
* Able to give informed written consent to participate.

Exclusion Criteria

* Unwilling to undergo cystectomy.
* Previous abdominal surgery rendering them unsuitable for either iRARC or ORC.
* Patients with upper urinary tract disease
* Concomitant disease that would render the patient unsuitable for the trial
* Pregnant or lactating females
* Previous radiotherapy for bladder cancer

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No